Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Accumulated Expenses (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Other Accumulated Expenses data on record, last reported at $16.5 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 20.03% year-over-year to $16.5 million; the TTM value through Dec 2025 reached $16.5 million, down 20.03%, while the annual FY2025 figure was $16.5 million, 20.03% down from the prior year.
  • Other Accumulated Expenses reached $16.5 million in Q4 2025 per PTCT's latest filing, down from $17.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $28.3 million in Q2 2025 and bottomed at $1.2 million in Q3 2021.
  • Average Other Accumulated Expenses over 5 years is $11.5 million, with a median of $11.3 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 74.32% in 2021, then skyrocketed 755.32% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $12.6 million in 2021, then dropped by 4.63% to $12.1 million in 2022, then dropped by 11.45% to $10.7 million in 2023, then soared by 92.97% to $20.6 million in 2024, then fell by 20.03% to $16.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $16.5 million in Q4 2025, $17.4 million in Q3 2025, and $28.3 million in Q2 2025.